Dublin's 15 Most Active VCs for Startups in 2026

Last updated: April 2026

We built Peony — an AI-powered data room — and I see how Dublin startups share their fundraising materials every day. Dublin punches above its weight: deep local seed funds, life-sciences specialists, global firms with Irish offices, and powerful state co-investors. This guide maps the firms that are actually deploying capital right now, so you can focus your outreach where it matters.

1) How to Pick the Right Dublin Investor (Fast Filter)

• Start with stage + ticket. Decide whether you need pre-seed/seed (Frontline Seed, Delta, Furthr-adjacent peers), A/B (ACT, Elkstone, Sure Valley), or deep-tech/life-sciences (Atlantic Bridge/University Bridge, Lightstone, Fountain, Seroba). Frontline raised a new seed vehicle in 2024; Elkstone runs a €100M early-stage fund; Seroba and Fountain are actively deploying dedicated life-sciences funds. (TechCrunch)
• Prioritise fresh dry powder + recent activity. Look for new closes and first-closes in 2024-2026 across Dublin firms: Frontline's seed fund, Sure Valley's Irish software fund first close, and Elkstone's €100M early-stage vehicle. (TechCrunch)
• Use Ireland's public co-investment edge. Enterprise Ireland invests directly via the Pre-Seed Start Fund (€50K/€100K) and backs HPSUs (up to ~€1.2M), often catalysing private VCs. (Enterprise Ireland)
• Match thesis, not logo. AI/cyber/immersive? Sure Valley Ventures. University spinouts/deep tech? Atlantic Bridge's University Bridge Fund. Medtech/biotech? Seroba, Fountain, Lightstone (Dublin office). (Silicon Republic)
• Ask for leverage beyond the cheque. Dublin investors are unusually plugged into UK/EU follow-on and US market access — Frontline explicitly optimises for transatlantic expansion. (Frontline)
• Share materials professionally. Instead of email attachments or consumer file-sharing links, use Peony to share a secure data room with your pitch deck, metrics, and materials. Peony provides identity-bound access, password protection, watermarking, and analytics to see who opened your materials before meetings.

2) The Investors (What They Do, Why Founders Pick Them, How to Approach)

VC funding into Irish SMEs fell 23% to EUR 1.1B in 2025 (from a record EUR 1.48B in 2024) — the first annual decline since 2018, driven by US investor hesitation around tariffs and AI capital concentration (IVCA VenturePulse, February 2026). But Q1 2026 shows recovery: globally, startups raised a record $297B in Q1 2026, with the UK and Ireland receiving significant allocations (Crunchbase, April 2026). Budget 2026 raised the R&D tax credit from 30% to 35% and the Entrepreneur Relief CGT lifetime cap from EUR 1M to EUR 1.5M.

For each: Focus and stage, typical motion, why founders pick them, pitch angle. Facts and 2024-2026 signals cited.

1) Atlantic Bridge (Dublin HQ)

Focus and stage: Growth-equity and deep tech across EU/US; more than EUR 1B AUM; Dublin office listed. (Atlantic Bridge) Typical motion: Leads and co-leads; strong cross-border scaling playbook. Why founders pick them: Global network + the University Bridge pipeline (see #2). 2026 signal: Participated in Equal1's $60M round (January 2026) — a UCD spinout building silicon-based quantum computers, co-invested with ISIF and Enterprise Ireland (Silicon Republic). Also continued investor in Neurent Medical's EUR 62.5M oversubscribed Series C (February 2026). Pitch angle: Show a "wedge to platform" plan and which US/EU lighthouse accounts you will win next.

2) University Bridge Fund (I and II) — Managed by Atlantic Bridge

Focus and stage: University spin-outs from Ireland's top institutions; €80M Fund II targeting AI/robotics/quantum/healthtech; EI, EIF, AIB among backers. (Enterprise Ireland) Typical motion: Pre-seed/seed through Series A, hands-on with tech transfer. Why founders pick them: Category-specific company-building and lab-to-market know-how. Pitch angle: TRL to customers: validation, IP, regulatory path, and 12-month industry pilots.

3) Frontline Ventures (Dublin)

Focus and stage: Seed (EU) and Growth (US to EU); 2024 raised a new seed fund to back B2B founders aiming at Series A. (TechCrunch) Typical motion: Leads at seed; helps compress the A-raise timeline. Why founders pick them: Transatlantic expansion engine. (Frontline) 2026 signal: Participated in Tucuvi's $20M Series A (January 2026) — a Madrid-based clinical voice AI company processing 300K+ patient calls across 60+ healthcare organizations (Tech.eu). Pitch angle: Deliver repeatability by segment (ICP, channels, payback) and named US/EU pipeline.

4) ACT Venture Capital (Dublin)

Focus and stage: Seed through expansion across tech; ACT VI initially closed at ~€140M; capacity to invest up to ~€10M per company. (Waveup) Typical motion: Leads A/B; disciplined ownership and follow-ons. Why founders pick them: Long track-record with notable Irish exits. Pitch angle: Cohort retention + sales system (quotas, win rates, ramp) mapped to next 18 months.

5) Delta Partners (Dublin)

Focus and stage: Seed/early-stage tech; EUR 70M fund (first close 2022) to back ~30 startups with Bank of Ireland and Enterprise Ireland as cornerstone LPs. (The Irish Times) Typical motion: Leads/co-leads seed; pragmatic on valuation with reserves for A. Why founders pick them: Deep Ireland network; company-building at formative stages. 2026 signal: Led Kayna's EUR 1.5M seed (March 2026) — a Cork-based embedded insurance infrastructure platform launching in UK and US (Silicon Republic). Two portfolio companies (Imvizar and VisionR) named in WIRED's Europe's hottest startups. Pitch angle: Design-partner letters + weekly activation and usage curves.

6) Elkstone (Dublin)

Focus and stage: Broad early-stage; EUR 100M Venture Fund I (largest Irish early-stage fund); typical initial cheques EUR 1-2M. Venture Fund II targeting EUR 150-200M as Ireland's first all-island fund. (isif.ie) Typical motion: Leads/co-leads seed and A; active co-investment model. Why founders pick them: Firepower to keep supporting winners across rounds. 2026 signal: New CEO Joe Bergin took over from founder Alan Merriman in January 2026 (Irish Times, February 2026). Led Overpath's EUR 1.6M round (January 2026) — an AI sales execution platform, co-invested with Sure Valley Ventures (Silicon Republic). Co-invested in Equal1's $60M quantum computing round. Pitch angle: Show capital efficiency and a crisp plan to hit A-readiness in 12 months.

7) Sure Valley Ventures (Dublin and Waterford)

Focus and stage: Irish software/AI, cyber, immersive; Irish fund first close EUR 30M (2023) targeting ~15 companies, backed by Enterprise Ireland. (FinSMEs) Typical motion: Pre-seed/seed; hands-on with early GTM + talent. Why founders pick them: Focused thesis + Irish pipeline; active 2024-2026 deployments. (PitchBook) 2026 signal: Co-invested in Overpath EUR 1.6M (January 2026, AI sales execution, with Elkstone). Participated in Captur's $6M seed (March 2026) — an NYC-based edge AI company for enterprise mobile apps (FinSMEs). Pitch angle: Problem to ICP to channel clarity, with early security/AI governance notes.

8) Lightstone Ventures (Ireland) — Dublin Office

Focus and stage: Global life-sciences (biotech and medtech) with offices in the US and Ireland; active Irish board roles and syndicates. (lightstonevc.com) Typical motion: Leads/co-leads across clinical stages with US/EU syndicate partners. Why founders pick them: Deep clinical/regulatory networks and transatlantic co-investors. Pitch angle: Value-inflection plan (IND/CE/clinical endpoints) and KOL traction.

9) Fountain Healthcare Partners (Dublin)

Focus and stage: Life-sciences specialist; Fund III EUR 125M (final close), Fund IV now deploying, total AUM ~EUR 400M+; active in devices/biopharma. (Fountain Healthcare Partners) Typical motion: Series A/B with meaningful reserves. Why founders pick them: Experienced operators with high-signal syndicates. 2026 signal: New investment in Exciva's EUR 51M Series B (January 2026) — a German biotech developing a treatment for agitation in Alzheimer's patients (Fountain Healthcare). Continued investor in Neurent Medical's EUR 62.5M oversubscribed Series C (February 2026) — a Galway medtech accelerating the NEUROMARK System for chronic rhinitis (PR Newswire). Pitch angle: Clinical + reimbursement pathway and comparator economics.

10) Seroba Life Sciences (Dublin HQ)

Focus and stage: European biotech/medtech; Fund IV EUR 123M (2024 final close); Dublin headquarters explicitly noted. (Seroba Lifesciences) Typical motion: Early through growth; concentrated portfolio support. Why founders pick them: Hands-on life-sciences builders with recent Irish and EU deals. 2026 signal: Participated in Alveus Therapeutics' $37M Series A extension (February 2026), bringing the total round to $197M — next-generation obesity and metabolic disease therapies, alongside Novo Holdings, Jeito Capital, and Sanofi Capital (Yahoo Finance). Pitch angle: Clear mechanism to endpoints to partnering line of sight for the next 12-18 months.

State co-investor to know: Enterprise Ireland — beyond grants, EI directly invests via PSSF (€50K/€100K) and HPSU (up to ~€1.2M); 2026 directory highlights continued direct startup backing. Use EI to crowd-in private VCs and extend runway. (Enterprise Ireland)

3) Five Quick Tips to Land Dublin Term Sheets

1. Lead with retention, not adjectives. One slide: activation through D30/D60/D90 retention, cohort payback, and what this round buys in milestones.
2. Bring 2 proofs that travel. A design-partner letter and a paid pilot (or KOL/clinical data if life-sciences). Tie to follow-on readiness.
3. Use EI cleverly. Show how PSSF/HPSU participation or EI-anchored funds (e.g., Sure Valley) extend runway and de-risk the next round. (Enterprise Ireland)
4. Transatlantic narrative. Dublin investors care about crossing borders — Frontline and Atlantic Bridge optimise for EU-to-US expansion. Name the first 3 lighthouse customers and your entry plan. (Frontline)
5. Keep the data room boring. Clean cap table, IP, customer letters, cohort tables, and a milestone-indexed budget. "Boring" wins diligence. Use Peony for secure investor data rooms with AI-powered Q&A and page-level analytics to accelerate investor conversations.

Closing

Dublin's VC ecosystem is compact enough that founders can map every relevant fund in a weekend — but deep enough that there is real specialisation by stage, sector, and geography. The firms above are actively deploying in 2026. Start with the 2-3 that match your stage and thesis, lead with proof points, and lean on Enterprise Ireland's co-investment edge to fill gaps.

If you need a clean place to organise your deck, metrics, and legal documents before approaching these firms, Peony sets up a data room in under five minutes with AI auto-indexing.

Frequently Asked Questions

We're a Dublin SaaS startup raising a Series A — should we talk to Frontline or ACT first?

It depends on where you are in your GTM. If you have early US pipeline and want a transatlantic expansion partner, Frontline is purpose-built for that — they raised a dedicated seed fund to compress the seed-to-A timeline. If you already have repeatable Irish/EU revenue and need a disciplined Series A lead with capacity up to ~€10M per company, ACT VI is the better fit. Approach both, but sequence your outreach based on which story is stronger today. When you share materials, set up your data room in Peony so you get page-level analytics showing which sections each partner actually read.

How does Enterprise Ireland co-investment work, and can I use it to get VCs interested?

Enterprise Ireland invests directly through the Pre-Seed Start Fund (€50K/€100K) and the HPSU programme (up to ~€1.2M). The real leverage is signaling: when EI commits, private VCs see validated commercial potential and reduced risk. Several Dublin funds — Sure Valley, Delta, University Bridge — have EI as a cornerstone LP, so EI backing makes warm intros to those GPs natural. Stage your EI application early so the commitment letter is in hand when you pitch. Share the EI term sheet alongside your deck using Peony dynamic watermarks so each investor sees their name on every page — it signals you take confidentiality seriously.

Our biotech startup is pre-clinical. Which Dublin VCs actually understand life sciences?

Three Dublin-based firms specialise. Seroba Life Sciences (Fund IV, €123M final close in 2024) focuses on European biotech/medtech from early through growth. Fountain Healthcare Partners (Fund III, €125M, ~€300M+ total AUM) leads Series A/B with deep clinical reserves. Lightstone Ventures has a Dublin office and global life-sciences reach with US syndication. For pre-clinical, Seroba and Fountain are your best first calls — both value mechanism-of-action clarity and a realistic endpoints timeline over revenue metrics. When sharing clinical data with multiple firms simultaneously, use Peony NDA gates to require each VC to sign a confidentiality agreement before viewing sensitive preclinical results.

I'm a first-time founder in Dublin with a prototype but no revenue. Who will actually take the meeting?

At pre-revenue, focus on three paths. First, Enterprise Ireland's Pre-Seed Start Fund (€50K/€100K) is designed exactly for your stage and validates you for private VCs. Second, Sure Valley Ventures (Irish fund, €30M first close) invests at pre-seed/seed in software, AI, and cyber — they care about problem-ICP-channel clarity, not revenue. Third, if you are a university spinout, University Bridge Fund II (€80M) specifically backs Irish research commercialisation. For all three, prepare a clean deck, IP summary, and prototype demo in a single shareable link. Peony AI auto-indexing organises your uploaded documents in under three minutes, so you spend time on the pitch instead of file management.

We're planning to expand from Dublin to the US. Which VCs have real transatlantic networks?

Two firms stand out. Frontline Ventures explicitly optimises for EU-to-US expansion — their growth fund backs B2B companies entering the US market, and their portfolio support includes US GTM coaching and customer intros. Atlantic Bridge has offices in Dublin and Silicon Valley with more than €1B AUM and a scaling playbook built around cross-border lighthouse accounts. Both will want to see named US prospects, not just a vague expansion plan. Prepare a US market entry memo in your data room alongside your core deck. With Peony access revocation, you can share sensitive US pipeline details with shortlisted VCs and instantly revoke access if a conversation goes cold.

How much do Dublin VCs typically invest at seed versus Series A?

Typical Dublin seed cheques range from €250K to €2M. Frontline and Delta lead seed rounds in that range, while Elkstone's €100M fund writes €1-2M initial cheques with reserves for follow-on. At Series A, ACT Venture Capital can deploy up to ~€10M per company through ACT VI (€140M+ fund), and Fountain writes larger cheques in life sciences. The gap between seed and A is where most Dublin startups stall, so show your bridge plan. When structuring your data room for multiple round conversations, use Peony e-signatures so term sheets and side letters can be executed directly inside the room without switching to a separate signing tool.

What should go in our data room before approaching Dublin VCs?

Dublin VCs expect six core items: a clean cap table, IP assignment documentation, cohort metrics (activation through D30/D60/D90 retention and payback), two or more proof points that travel (design-partner letters, paid pilots, or clinical data for life sciences), a milestone-indexed budget for this round, and your Enterprise Ireland status or application. Keep it organised by section, not chronologically. Peony AI Q&A lets investors ask questions in plain English and get instant answers with cited page numbers, so you avoid the back-and-forth email chains that slow down diligence.

Is it worth approaching Dublin VCs if our startup is outside Ireland but wants Irish customers?

Yes, but be strategic about which firms. Atlantic Bridge and Frontline invest across the EU, not just in Irish-domiciled companies — your Dublin traction or customer base gives you a narrative they value. Elkstone and ACT are more Ireland-focused but will consider companies with meaningful Irish operations. The key is showing that Dublin is a genuine market for you, not just a flag-of-convenience. When sharing materials with investors across multiple jurisdictions, Peony screenshot protection blocks and logs any attempt to capture your documents — useful when your deck contains market data you do not want circulating.

Related Resources

• How to Send a Pitch Deck to Investors
• How to Track Pitch Deck Engagement
• VC Fund Data Room Checklist
• Data Room for Investors
• Investor Outreach Plan: 8 Steps
• How to Protect Your Pitch Deck